Baiteng Zhao
赵柏腾
Baiteng Zhao (赵柏腾) is the co-founder, CEO, and chairman of ProfoundBio (普方生物), a biotech company developing antibody-drug conjugate (ADC) cancer therapies . Under his leadership the company raised an oversubscribed $55 million Series A in 2021 , a $70 million Series A+ in 2022 , and a $112 million Series B in February 2024 to push its ADC candidates into pivotal clinical development . Just two months after the Series B, in April 2024, Danish drugmaker Genmab acquired ProfoundBio for $1.8 billion — at the time, Zhao said Genmab and his team shared a mission of "developing innovative therapies to improve outcomes for cancer patients" . The funding and acquisition announcements above were carried by Gaorong Ventures, an investor in the company.
AI-generated — may contain errors, please verify.
Coverage
Genmab Acquires ProfoundBio for $1.8 Billion | Gaorong Ventures News
Accelerate the development and unlock the full potential of ADC therapies.
ProfoundBio Closes $112 Million Series B to Advance ADC Drug Candidates Into Pivotal Clinical Development
Delivering breakthrough therapies for cancer patients.
ProfoundBio Closes $70 Million Series A+ Round to Advance Novel Antibody-Drug Conjugate Clinical Development
Accelerate preclinical development across multiple pipelines while further deepening and expanding the ADC innovative technology platform.
Platonic Bio Closes Oversubscribed $55 Million Series A to Accelerate ADC Drug and Immuno-Oncology Platform Development
Enabling best-in-class and first-in-class ADCs to advance into clinical development.
